nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

22.01.2021 | Original Article

Relationship of Cardiac Autonomic Modulation with Cardiovascular Parameters in Adults, According to Body Mass Index and Physical Activity

verfasst von: William R. Tebar, Raphael M. Ritti-Dias, Jorge Mota, Bruna T. C. Saraiva, Tatiana M. Damato, Leandro D. Delfino, Breno Q. Farah, Luiz Carlos M. Vanderlei, Diego G. D. Christofaro

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to analyze the relationship between cardiac autonomic modulation (CAM) and cardiovascular parameters (blood pressure and resting heart rate) in a sample of 256 adults, grouped by body mass index and sufficient moderate-to-vigorous physical activity (≥150 min/week). The sample showed different cardiovascular parameters and CAM according to body mass index, but not according to physical activity. Adults who are overweight and physically active presented higher relationship between CAM and blood pressure than those who are insufficiently active, similarly to normal weight groups. Recommended levels of physical activity may play an important role in the relationship of HRV with cardiovascular parameters in overweight adults, regardless of sex, age, socioeconomic level, and central fat. Trial registration: Registered at ClinicalTrials.gov (NCT03986879).

Thayer, J. F., Yamamoto, S. S., & Brosschot, J. F. (2010). The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. International Journal of Cardiology, 141(2), 122–131. https://doi.org/10.1016/j.ijcard.2009.09.543.CrossRefPubMed

Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J (1996) 17(3):354–81.https://doi.org/10.1093/oxfordjournals.eurheartj.a014868

Saito, I., Takata, Y., Maruyama, K., et al. (2018). Association between heart rate variability and home blood pressure: The Toon health study. American Journal of Hypertension, 31(10), 1120–1126. https://doi.org/10.1093/ajh/hpy100.CrossRefPubMed

Hart, J. (2013). Association between heart rate variability and manual pulse rate. J Can Chiropr Assoc., 57(3), 243–250.PubMedPubMedCentral

Fuchs, F. D., & Whelton, P. K. (2020). High blood pressure and cardiovascular disease. Hypertension., 75(2), 285–292. https://doi.org/10.1161/HYPERTENSIONAHA.119.14240.CrossRefPubMed

Aune, D., Sen, A., ó'Hartaigh, B., et al. (2017). Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality - a systematic review and dose-response meta-analysis of prospective studies. Nutrition, Metabolism, and Cardiovascular Diseases, 27(6), 504–517. https://doi.org/10.1016/j.numecd.2017.04.004.CrossRefPubMed

Casonatto, J., Tinucci, T., Dourado, A. C., & Polito, M. (2011). Cardiovascular and autonomic responses after exercise sessions with different intensities and durations. Clinics (São Paulo, Brazil), 66(3), 453–458. https://doi.org/10.1590/s1807-59322011000300016.CrossRef

Rossi, R. C., Vanderlei, L. C., Gonçalves, A. C., et al. (2015). Impact of obesity on autonomic modulation, heart rate and blood pressure in obese young people. Autonomic Neuroscience, 193, 138–141. https://doi.org/10.1016/j.autneu.2015.07.424.CrossRefPubMed

Prince, S. A., Adamo, K. B., Hamel, M. E., Hardt, J., Connor Gorber, S., & Tremblay, M. (2008). A comparison of direct versus self-report measures for assessing physical activity in adults: A systematic review. International Journal of Behavioral Nutrition and Physical Activity, 5, 56.CrossRef

10.

Tebar, W. R., Ritti-Dias, R. M., Saraiva, B. T. C., et al. (2019). The relationship between physical activity intensity and domains with cardiac autonomic modulation in adults: An observational protocol study. Medicine (Baltimore), 98(41), e17400. https://doi.org/10.1097/MD.0000000000017400.CrossRef

11.

Giles, D., Draper, N., & Neil, W. (2016). Validity of the polar V800 heart rate monitor to measure RR intervals at rest. European Journal of Applied Physiology, 116(3), 563–571. https://doi.org/10.1007/s00421-015-3303-9.CrossRefPubMed

12.

Catai, A. M., Pastre, C. M., Godoy, M. F., Silva, E. D., Takahashi, A. C. M., & Vanderlei, L. C. M. (2020). Heart rate variability: Are you using it properly? Standardisation checklist of procedures. Brazilian Journal of Physical Therapy, 24(2), 91–102. https://doi.org/10.1016/j.bjpt.2019.02.006.CrossRefPubMed

13.

Cilhoroz, B., Giles, D., Zaleski, A., Taylor, B., Fernhall, B., & Pescatello, L. (2020). Validation of the polar V800 heart rate monitor and comparison of artifact correction methods among adults with hypertension. PLoS One, 15(10), e0240220. https://doi.org/10.1371/journal.pone.0240220.CrossRefPubMedPubMedCentral

14.

Troiano, R. P., Berrigan, D., Dodd, K. W., et al. (2008). Physical activity in the United States measured by accelerometer. Medicine and Science in Sports and Exercise, 40, 181–188.CrossRef

15.

Trost, S. G., McIver, K. L., & Pate, R. R. (2005). Conducting accelerometer-based activity assessments in field-based research. Medicine and Science in Sports and Exercise, 3711(Suppl), S531–S543.CrossRef

16.

Sasaki, J. E., John, D., & Freedson, P. S. (2011). Validation and comparison of ActiGraph activity monitors. Journal of Science and Medicine in Sport, 14, 411–416.CrossRef

17.

World Health Organisation . Global Recommendations on Physical Activity for Health. World Health Organisation; Geneva, Switzerland: 2010. Retrieved from: http://apps.who.int/iris/bitstream/handle/10665/44399/9789241599979_eng.pdf;jsessionid=1892C5EA4A6C4B6EF81ECBD614B2C1FB?sequence=1.

18.

WHO. Physical Status: The Use and Interpretation of Anthropometry: Report of a World Health Organization (WHO) Expert Committee. Geneva, Switzerland: World Health Organization; (1995).

19.

ABEP- Brazilian Association of Researchh Companies. Brazilian Criteria for Economic Classification (2015). Retrieved from: http://www.abep.org/criterio-brasil.

20.

Gamez-Mendez, A. M., Vargas-Robles, H., Rios, A., & Escalante, B. (2015). Oxidative stress-dependent coronary endothelial dysfunction in obese mice. PLoS One, 10(9), e0138609. https://doi.org/10.1371/journal.pone.0138609.CrossRefPubMedPubMedCentral

21.

Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004 Dec). Increased oxidative stress in obesity and its impact on metabolic syndrome. The Journal of Clinical Investigation, 114(12), 1752–1761.CrossRef

22.

Wohlfahrt, P., Somers, V. K., Cifkova, R., Filipovsky, J., Seidlerova, J., Krajcoviechova, A., Sochor, O., Kullo, I. J., & Lopez-Jimenez, F. (2014 Aug). Relationship between measures of central and general adiposity with aortic stiffness in the general population. Atherosclerosis., 235(2), 625–631.CrossRef

23.

Burke, G. L., Bertoni, A. G., Shea, S., Tracy, R., Watson, K. E., Blumenthal, R. S., Chung, H., & Carnethon, M. R. (2008 May 12). The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: The multi-ethnic study of atherosclerosis. Archives of Internal Medicine, 168(9), 928–935.CrossRef

24.

Ventura, H. O., Taler, S. J., & Strobeck, J. E. (2005 Feb). Hypertension as a hemodynamic disease: The role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. American Journal of Hypertension, 18(2 Pt 2), 26S–43S.CrossRef

25.

Caillon, A., & Schiffrin, E. L. (2016 Mar). Role of inflammation and immunity in hypertension: Recent epidemiological, laboratory, and clinical evidence. Current Hypertension Reports, 18(3), 21.CrossRef

26.

Huby, A. C., Antonova, G., Groenendyk, J., Gomez-Sanchez, C. E., Bollag, W. B., & Filosa, J. A. (2015 Dec 1). Belin de Chantemèle EJ. Adipocyte-derived hormone Leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation., 132(22), 2134–2145.CrossRef

27.

Buglioni, A., Cannone, V., Cataliotti, A., Sangaralingham, S. J., Heublein, D. M., Scott, C. G., Bailey, K. R., Rodeheffer, R. J., Dessì-Fulgheri, P., Sarzani, R., & Burnett Jr., J. C. (2015 Jan). Circulating aldosterone and natriuretic peptides in the general community: Relationship to cardiorenal and metabolic disease. Hypertension., 65(1), 45–53.CrossRef

28.

Cassis, L. A., Police, S. B., Yiannikouris, F., & Thatcher, S. E. (2008 Apr). Local adipose tissue renin-angiotensin system. Current Hypertension Reports, 10(2), 93–98.CrossRef

29.

Draghici, A. E., & Taylor, J. A. (2016 Sep 28). The physiological basis and measurement of heart rate variability in humans. Journal of Physiological Anthropology, 35(1), 22.CrossRef

30.

Mayet, J., & Hughes, A. (2003). Cardiac and vascular pathophysiology in hypertension. Heart., 89(9), 1104–1109. https://doi.org/10.1136/heart.89.9.1104.CrossRefPubMedPubMedCentral

31.

Routledge, F. S., Campbell, T. S., McFetridge-Durdle, J. A., & Bacon, S. L. (2010). Improvements in heart rate variability with exercise therapy. The Canadian Journal of Cardiology, 26(6), 303–312. https://doi.org/10.1016/s0828-282x(10)70395-0.CrossRefPubMedPubMedCentral

32.

Migueles, J. H., Cadenas-Sanchez, C., Ekelund, U., et al. (2017). Accelerometer data collection and processing criteria to assess physical activity and other outcomes: A systematic review and practical considerations. Sports Medicine, 47(9), 1821–1845. https://doi.org/10.1007/s40279-017-0716-0.CrossRefPubMed

33.

Herzig, D., Eser, P., Omlin, X., Riener, R., Wilhelm, M., & Achermann, P. (2018 Jan 10). Reproducibility of heart rate variability is parameter and sleep stage dependent. Frontiers in Physiology, 8, 1100. https://doi.org/10.3389/fphys.2017.01100.CrossRefPubMedPubMedCentral

34.

Sinnreich, R., Kark, J. D., Friedlander, Y., Sapoznikov, D., & Luria, M. H. (1998). Five minute recordings of heart rate variability for population studies: Repeatability and age-sex characteristics. Heart., 80(2), 156–162. https://doi.org/10.1136/hrt.80.2.156.CrossRefPubMedPubMedCentral

35.

Tebar WR, Ritti-Dias RM, Mota J, et al. Relationship between domains of physical activity and cardiac autonomic modulation in adults: a cross-sectional study. Sci Rep. 2020;10(1):15510. Published 2020 Sep 23. doi:https://doi.org/10.1038/s41598-020-72663-7

36.

Schroeder, E. B., Liao, D., Chambless, L. E., Prineas, R. J., Evans, G. W., & Heiss, G. (2003). Hypertension, blood pressure, and heart rate variability: The atherosclerosis risk in communities (ARIC) study. Hypertension., 42(6), 1106–1111. https://doi.org/10.1161/01.HYP.0000100444.71069.73.CrossRefPubMed

37.

Singh, J. P., Larson, M. G., Tsuji, H., Evans, J. C., O'Donnell, C. J., & Levy, D. (1998). Reduced heart rate variability and new-onset hypertension: Insights into pathogenesis of hypertension: The Framingham heart study. Hypertension., 32(2), 293–297. https://doi.org/10.1161/01.hyp.32.2.293.CrossRefPubMed

38.

Kubota Y, Chen LY, Whitsel EA, Folsom AR. Heart rate variability and lifetime risk of cardiovascular disease: the Atherosclerosis Risk in Communities Study. Ann Epidemiol. 2017;27(10):619–625.e2. doi:https://doi.org/10.1016/j.annepidem.2017.08.024

39.

Zhang, D. Y., & Anderson, A. S. (2014). The sympathetic nervous system and heart failure. Cardiology Clinics, 32(1), 33–vii. https://doi.org/10.1016/j.ccl.2013.09.010.CrossRefPubMedPubMedCentral

40.

Bibevski, S., & Dunlap, M. E. (2011). Evidence for impaired vagus nerve activity in heart failure. Heart Failure Reviews, 16(2), 129–135. https://doi.org/10.1007/s10741-010-9190-6.CrossRefPubMed

41.

Azizian, M., Mahdipour, E., Mirhafez, S. R., et al. (2016). Cytokine profiles in overweight and obese subjects and normal weight individuals matched for age and gender. Annals of Clinical Biochemistry, 53(6), 663–668. https://doi.org/10.1177/0004563216629997.CrossRefPubMed

42.

Ellulu, M. S., Patimah, I., Khaza'ai, H., Rahmat, A., & Abed, Y. (2017). Obesity and inflammation: The linking mechanism and the complications. Archives of Medical Science, 13(4), 851–863. https://doi.org/10.5114/aoms.2016.58928.CrossRefPubMed

43.

Pongratz, G., & Straub, R. H. (2014). The sympathetic nervous response in inflammation. Arthritis Research & Therapy, 16(6), 504. https://doi.org/10.1186/s13075-014-0504-2.CrossRef

44.

Pavlov, V. A., & Tracey, K. J. (2012). The vagus nerve and the inflammatory reflex--linking immunity and metabolism. Nature Reviews. Endocrinology, 8(12), 743–754. https://doi.org/10.1038/nrendo.2012.189.CrossRefPubMedPubMedCentral

Titel: Relationship of Cardiac Autonomic Modulation with Cardiovascular Parameters in Adults, According to Body Mass Index and Physical Activity
verfasst von: William R. Tebar
Raphael M. Ritti-Dias
Jorge Mota
Bruna T. C. Saraiva
Tatiana M. Damato
Leandro D. Delfino
Breno Q. Farah
Luiz Carlos M. Vanderlei
Diego G. D. Christofaro
Publikationsdatum: 22.01.2021
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 5/2021
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-021-10101-3

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Relationship of Cardiac Autonomic Modulation with Cardiovascular Parameters in Adults, According to Body Mass Index and Physical Activity

Abstract

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Computed Tomography Angiography for the Diagnosis of Coronary Artery Disease Among Patients Undergoing Transcatheter Aortic Valve Implantation

Impact of Left Atrial Sphericity Index on the Outcome of Catheter Ablation for Atrial Fibrillation

The Prognostic Value of a Validated and Automated Intravascular Ultrasound-Derived Calcium Score

CTA-Based Non-invasive Estimation of Pressure Gradients Across a CoA: a Validation Against Cardiac Catheterisation

Sociodemographic Characteristics Predicting Digital Health Intervention Use After Acute Myocardial Infarction

Phosphodiesterase-5a Knock-out Suppresses Inflammation by Down-Regulating Adhesion Molecules in Cardiac Rupture Following Myocardial Infarction

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie